Tanshinone I and Tanshinone IIA/B attenuate LPS-induced mastitis via regulating the NF-κB

Yang, Lili; Zhou, Guanglin; Liu, Jinghua; Song, JinShuang; Zhang, Zongyu; Huang, Qi; Wei, Fengxiang

doi:10.1016/j.biopha.2021.111353

Cited by 32 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tanshinone IIA (Tan IIA) was an active component that separated from Danshen (a traditional medication) [ 8 , 9 ]. Tan IIA has antiapoptotic, antioxidant, and anticoagulant along with other effects and has been extensively utilized in treating cardiovascular as well as cerebrovascular diseases.…”

Section: Introductionmentioning

confidence: 99%

Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome

Zhang

Song

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Gastric cancer (GC) belongs to a type of the most deadly cancer in the world, and the incidence rate of GC will increase in the coming decades. Tanshinone IIA (Tan IIA) is an active component that separated from Danshen. Tan IIA may also exert its therapeutic effects in disease with intestinal dysbacteriosis, at least partially, via regulating the intestinal microbiome. Nevertheless, it is obscure whether Tanshinone IIA affects the intestinal dysbacteriosis and plays antitumor roles. This research was designed to explore Tanshinone IIA potential on the intestinal dysbacteriosis of GC xenograft mice. Methods. Mouse xenograft GC tumor models were built and treated by Tan IIA. The tumor growth as well as microbiome in the intestinal were compared. Western blot was used to detect the phosphorylation of the NF-κB and expressions of the downstream cytokines IL-6 and IL-1β. Results. Microbiome in the intestinal was changed in xenograft tumor mice in comparison with the control mice. What is more, Tan IIA could influence the microbiome in the intestinal of the tumor mice. Tan IIA hinders the growth of xenograft tumor and change the microbiome in the intestinal, but intestinal dysbacteriosis condition partially blocked Tan IIA-stimulated antitumor effects. In addition, intestinal dysbacteriosis abrogated Tan IIA-stimulated decrease in the NF-κB signaling in xenograft tumor mice. Conclusions. Tanshinone IIA may inhibit GC tumor growth via affecting the intestinal microbiome through regulating the NF-κB signaling.

show abstract

Section: Introductionmentioning

confidence: 99%

Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome

Zhang

Song

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Inhibition of NF-ĸB attenuates renal fibrosis in animal models [ 35 ]. The anti-inflammatory effect of Tan-I has been reported recently [ 36 ]. Tan-I inhibits IL-1β-induced NF-ĸB activation in chondrocytes, a model for osteoarthritis [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…Tan-I inhibits IL-1β-induced NF-ĸB activation in chondrocytes, a model for osteoarthritis [ 37 ]. Tan-I together with Tanshinone IIA/B attenuate LPS-induced inflammation in mastitis probably through the NF-κB signaling pathway [ 36 ]. Whether Tan-I inhibits renal fibrosis through the NF-κB signaling pathway should be investigated in the future.…”

Section: Discussionmentioning

confidence: 99%

Tanshinone I attenuates fibrosis in fibrotic kidneys through down-regulation of inhibin beta-A

Yang

Huang

et al. 2022

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Tanshinone I (Tan-I), an ingredient of Salvia miltiorrhiza, displays protective effects in several disease models. We aim to study the effect of Tan-I on renal fibrosis and explore its underlining mechanism. Methods Rat renal fibroblasts (NRK-49F) were used as an in vitro model to study the effect of Tan-I. Mouse renal fibrosis model was induced by unilateral ureteral obstruction (UUO) or peritoneally injection of aristolochic acid I (AAI). Results We found that Tan-I dose-dependently inhibited the expression of pro-fibrotic markers in rat renal fibroblasts. Masson staining and Western blotting analysis showed that Tan-I treatment attenuated renal fibrosis in UUO or AAI induced fibrotic kidneys. RNA sequencing analysis identified inhibin beta-A (INHBA), a ligand of TGF-β superfamily, as a downstream target of Tan-I in fibrotic kidneys, which were further verified by qPCR. Western blotting analysis showed that INHBA is up-regulated in UUO or AAI induced fibrotic kidneys and Tan-I reduced the expression of INHBA in fibrotic kidneys. Inhibition of INHBA by Tan-I was further confirmed in rat fibroblasts. Moreover, knockdown of INHBA reduced the expression of pro-fibrotic markers and abolished the ani-fibrotic effect of Tan-I in rat renal fibroblasts. Conclusions We conclude that Tan-I attenuates fibrosis in fibrotic kidneys through inhibition of INHBA.

show abstract

“…It has significant inhibitory effects against numerous kinds of malignancies such as colon cancer ( Lu et al, 2016 ), human endometrial cancer ( Li Q. et al, 2018 ), breast cancer ( Zheng et al, 2020 ), liver cancer ( Zheng et al, 2020 ), gastric cancer ( Jing et al, 2016 ), cervical cancer ( Dun and Gao, 2019 ), and so on. In addition, the compound has therapeutic effects on vascular diseases ( Wu Y. et al, 2019 ), arthritis ( Wang et al, 2019 ), mastitis ( Yang et al, 2021 ), and diabetes ( Wei et al, 2017 ). Tan I was studied earlier compared with other main active substances of tanshinones.…”

Section: Introductionmentioning

confidence: 99%

“…Its derivative sodium Tan IIA sulfonate has been comprehensively used in the clinic ( Ji et al, 2017 ; Li et al, 2017 ; Mao et al, 2019 ). Tan IIA showed numerous pharmacological effects such as anti-atherosclerosis ( Lu et al, 2021 ), protection of cardiomyocytes and cardiac function ( Gao et al, 2019 ; Zhang et al, 2019 ), improvement of diabetic osteoporosis ( Ma et al, 2019 ; Zhang et al, 2020 ), repair of acute blunt skeletal muscle injury ( Wang et al, 2020 ) and tibia cartilage dysplasia ( Yang et al, 2019 ), protection against oxidative stress-induced myocardial cell injury ( Yang G. et al, 2020 ), reduction of endometriosis ( Chen and Gong, 2020 ) and traumatic brain injury ( Huang et al, 2020 ), anti-allergy ( Heo and Im, 2019 ), prevention of nonalcoholic fatty liver ( Gao et al, 2021 ), mastitis ( Yang et al, 2021 ), arthritis ( Wang et al, 2019 ), and cerebral ischemia ( Tang et al, 2019 ). As per the anti-tumorigenic potential of Tan IIA, it inhibited the growth of colorectal cancer ( Xue et al, 2019 ; Liu et al, 2021 ), gastric cancer ( Xu Z. et al, 2018 ), cervical cancer ( Tong et al, 2020 ), laryngeal cancer ( Xu H. et al, 2018 ), nasopharyngeal cancer ( Wang et al, 2021 ), and ovarian cancer ( Li N. et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms

Zhao

Han

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer is one of the most deadly malignancies in women worldwide. Salvia miltiorrhiza, a perennial plant that belongs to the genus Salvia, has long been used in the management of cardiovascular and cerebrovascular diseases. The main anti-breast cancer constituents in S. miltiorrhiza are liposoluble tanshinones including dihydrotanshinone I, tanshinone I, tanshinone IIA, and cryptotanshinone, and water-soluble phenolic acids represented by salvianolic acid A, salvianolic acid B, salvianolic acid C, and rosmarinic acid. These active components have potent efficacy on breast cancer in vitro and in vivo. The mechanisms mainly include induction of apoptosis, autophagy and cell cycle arrest, anti-metastasis, formation of cancer stem cells, and potentiation of antitumor immunity. This review summarized the main bioactive constituents of S. miltiorrhiza and their derivatives or nanoparticles that possess anti-breast cancer activity. Besides, the synergistic combination with other drugs and the underlying molecular mechanisms were also summarized to provide a reference for future research on S. miltiorrhiza for breast cancer treatment.

show abstract

Tanshinone I and Tanshinone IIA/B attenuate LPS-induced mastitis via regulating the NF-κB

Cited by 32 publications

References 27 publications

Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome

Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome

Tanshinone I attenuates fibrosis in fibrotic kidneys through down-regulation of inhibin beta-A

Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms

Contact Info

Product

Resources

About